Literature DB >> 27855411

Leg Muscle Involvement in Facioscapulohumeral Muscular Dystrophy: Comparison between Facioscapulohumeral Muscular Dystrophy Types 1 and 2.

Dorothea Mair1, Monika Huegens-Penzel, Wolfram Kress, Christian Roth, Andreas Ferbert.   

Abstract

BACKGROUND: Facioscapulohumeral muscular dystrophy (FSHD) presents with 2 genetically distinct types. We describe for the first time the MRI patterns of leg muscle involvement in type 2 and compare it with type 1.
METHODS: The intramuscular fat content was assessed on lower extremity axial T1-weighted MRI scans in 6 FSHD1 and 5 FSHD2 patients.
RESULTS: Overall, the muscle involvement profile did not differ substantially between FSHD1 and FSHD2. In the thigh, the dorsomedial compartment including the semimembranosus, semitendinosus and adductor magnus was the most affected. The quadriceps was mostly spared, but isolated involvement of the rectus femoris was common. Fat infiltration in the distal soleus and the medial gastrocnemius with sparing of the lateral gastrocnemius was a common finding; involvement of the tibialis anterior was less frequent. A proximal-to-distal increase in fat content was frequently present in some muscles.
CONCLUSION: Muscle involvement appears to be independent of type, confirming a similar pathophysiological pathway in FSHD1 and FSHD2.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27855411     DOI: 10.1159/000452763

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  2 in total

1.  Use of muscle MRI in an atypical presentation of FSHD2.

Authors:  Aaron Jesuthasan; Sachit Shah; Jasper M Morrow
Journal:  BMJ Case Rep       Date:  2020-06-11

2.  Quantitative 1H and 23Na muscle MRI in Facioscapulohumeral muscular dystrophy patients.

Authors:  Teresa Gerhalter; Benjamin Marty; Lena V Gast; Katharina Porzelt; Rafael Heiss; Michael Uder; Stefan Schwab; Pierre G Carlier; Armin M Nagel; Matthias Türk
Journal:  J Neurol       Date:  2020-10-12       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.